Studies on Pyrazinoylguanidine

Pharmacology

Volumn 52, Issue 3, 1996, Pages 135-144

  A Rahim, Yousif I ^a   Beyer, Karl H ^a   Vesell, Elliot S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Antihyperglycemic drug; Antihyperlipidemic drug; Diabetes mellitus; Hydrochlorothiazide; Metformin; Plasma glucose; Plasma lipids; Pyrazinoylguanidine

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; FATTY ACID; GLUCAGON; GLUCOSE; GUANIDINE DERIVATIVE; HYDROCHLOROTHIAZIDE; PYRAZINOIC ACID DERIVATIVE; PYRAZINOYLGUANIDINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; FATTY ACID BLOOD LEVEL; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; INTRAPERITONEAL DRUG ADMINISTRATION; LIPID METABOLISM; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; GUANIDINES; HYDROCHLOROTHIAZIDE; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; STREPTOZOCIN;

EID: 0029869341     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139377     Document Type: Article

References (35)

1. Beck-Nielsen H, Groop L: Metabolie and genetic characterization of prediabetic states. J Clin Invest 1994;94:1714-1721.
2. Kuusisto J. Mykkanen L, Pyorala K. Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960-967.
3. Reavcn GM: Insulin resistance, hyperinsulinemia. hypertriglyceridemia, and hypertension: Parallels between human disease and rodent models. Diabetes Care 1991; 14: 195-202.
4. Kahn C: Insulin action, diabeto-genes. and the cause of type II diabetes. Diabetes 1994:43:1066-1084.
5. Reaven GM: The fourth Musketeer: From Alexander Dumas to Claude Bernard. Diabctologia 1995:38:3-18.
6. Groop L: Sulfonylurcas in NIDDM. Diabetes Care 1992;15:737-754.
7. Bailey C: Biguanides and NIDDM. Diabetes Care 1992;15:755-772.
8. Garg A, Grudy S: Management of dyslipidemia in NIDDM. Diabetic Care 1990;13:153-169.
9. Crouse JR: Hypertriglyceridemia: A contraindication to the use of bile acid binding resins. Am J Med 1987; 83:243-248.
10. Molnar G, Berge K. Rosevear J. McGuckin W. Achor R: The effect of nicotinic acid in diabetes mellitus. Metabolism 1964;13:181-189.
11. Vesell E, Chambers C. DeAngelo S. Passananti T, Demers L. Beyer K: Pyrazinoylguanidine down regulates the glucose fatty-acid cycle in hypertensive, hyperinsulinemic diabetic patients. J Clin Pharmacol 1994:34: 1234-1245.
12. Beyer K, Gclardcn T: Active transport of urea by mammalian kidney. Proc Natl Acad Sei USA 1988:85: 4030-4031.
13. Beyer K, Gelarden T. Vesell E: Inhibition of urea transport across renal tubules by pyrazinoylguanidine and analogs. Pharmacology 1992:45: 129-141.
14. Beyer K, Gelarden T, Vary J, Brown L, Vesell E: Novel multivalent effects of pyrazinoylguanidine in patients with azotemia. Clin Pharmacol Ther 1990;47:629-638.
15. Beyer K. Ward T, Vary J, Gclardcn T, Knutson D, Vesell E: Contrasting effects of pyrazinoylguanidine and hydrochlorothiazides in patients with renal insufficiency. J Clin Pharmacol 1993;33:554-561
16. Vesell E, Chambers C, Passananti T, Demers L. Beyer K: Effects of pyra-zinoylguanidine on the glucose-fatty acid cycle in normal subjects and patients with non-insulin-depen-dent diabetes mellitus. J Clin Pharmacol 1993;33:823-831.
17. Chambers C, Vesell E, Helm C, Passananti T. Beyer K: Pyrazinoylguanidine: Antihypertensive, hypocho-lesterolcmic. and renin effects. J Clin Pharmacol 1992;32:1128-1134.
18. Passananti T, Vesell E, Jeszenka E, Gclardcn T, Beyer K: Pharmco-kinetics of pyrazinoylguanidine, 3-aminopyrazinoylguanidinc and their corresponding pyrazinoic acid metabolites in humans and dogs. Pharmacology 1992;45:129-141.
19. Lithell H: Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991: 14:203-209.
20. Hoskins B. Jackson C: The mechanism of chlorothiazide-induced carbohydrate intolerance. J Pharmacol Exp Ther 1978;206:423-430.
21. A-Rahim Y, Beyer K, Vesell E: Studies on pyrazinoylguanidine. II: Comparative drug and dose effects on glucose and lipid metabolism in strcptozotocin-induced diabetic rats. Pharmacology 1996:52:148-155.
22. Zucker L. Zucker T: Fatty, a new mutation in the rat. J Hered 1961; 52:275-278.
23. Kava R, Greenwood M, Johnson P: Zucker(fa/fa) rat. ILAR News 1990; 32(3):4-8.
24. Peterson R, Shaw W, Neel M, Little L. Eichberg J: Zucker diabetic fatty rat as a model for non-insulin-dc-pendent diabetes mellitus. ILAR News 1990:32(3): 16-19.
25. Bray G: The Zucker-fatty rat: A review. Fed Proc 1977;36:148-153.
26. Stem J, Johnson P, Greenwood M, Zucker L. Hirsch J: Insulin resistance and pancreatic insulin release in the genetically obese Zucker rat. Proc Soc Exp Biol Med 1972; 139: 66-69.
27. Clark J, Palmer C, Shaw W: The diabetic zuckcr fatty rat (41611). Proc Soc Exp Biol Med 1983:173:68-75.
28. Reaven GM: Banting Lecture 1988: Role of Insulin resistance in human disease. Diabetes 1988;37:1595-1607.
29. Pilkis S. Park C: Mechanism of action of insulin. Annu Rev Pharmacol 1974;14:365-388.
30. Unger R: Role of glucagon in the pathogenesis of diabetes: The status of the controversy. Metabolism 1978;27:1691-1709.
31. Lefcbvre P, Luyckx A: Glucagon and diabetes: A reappraisal. Diabe-tologia 1979;16:347-354.
32. Stromblad G. Bjomtorp P: Reduced hepatic insulin clearance in rats with dietary-induced obesity. Metabolism 1986:35:323-327.
33. Fcrrannini E. Barrett E, Bcvilacqua S: Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983;72:1737-1747.
34. Randle P, Hales C, Garland P, Ncwsholme E: The glucose fatty-acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;i:785-789.
35. Havel R, Kane J, Baiasse E, et al: Splanchnic metabolism of free fatty acids and production of triglycerides of very low density lipoproteins in normotriglyceridemic and hvpcrtri-glyccridcmic humans. J Clin Invest 1970;49:2017-2035.